Dinaciclib

CAS No. 779353-01-4

Dinaciclib ( SCH 727965;SCH727965;SCH-727965 )

Catalog No. M15942 CAS No. 779353-01-4

A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 42 In Stock
5MG 68 In Stock
10MG 109 In Stock
50MG 348 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dinaciclib
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.
  • Description
    A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively; completely suppresses Rb phosphorylation and inhibits bromodeoxyuridine incorporation in >100 tumor cell lines; exhibits superior activity with an improved therapeutic index compared with flavopiridol.Blood Cancer Phase 3 Clinical
  • Synonyms
    SCH 727965;SCH727965;SCH-727965
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK1;CDK2;CDK5;CDK9
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    779353-01-4
  • Formula Weight
    396.49
  • Molecular Formula
    C21H28N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 56 mg/mL
  • SMILES
    OCC[C@H]1N(C2=NC3=C(CC)C=NN3C(NCC4=C[N+]([O-])=CC=C4)=C2)CCCC1
  • Chemical Name
    2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, (2S)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Parry D, et al. Mol Cancer Ther. 2010 Aug;9(8):2344-53.
2. Paruch K, et al. ACS Med Chem Lett. 2010 May 17;1(5):204-8.
3. Feldmann G, et al. Cancer Biol Ther. 2011 Oct 1;12(7):598-609.
4. Johnson AJ, et al. Leukemia. 2012 Dec;26(12):2554-7.
molnova catalog
related products
  • JH-VIII-49

    JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).

  • CDK4-IN-1

    CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.

  • Bohemine

    Bohemine is a cyclin-dependent kinase inhibitor.